Preview

Malignant tumours

Advanced search

MORPHOFUNCTIONAL CHARACTERISTICS OF HEMATOPOIETIC TISSUE IN LYMPHOMA PATIENTS

https://doi.org/10.18027/2224-5057-2018-8-2-5-11

Abstract

Parameters of ploidity and kinetics of cell cycle in bone marrow samples of lymphoma patients were studied by flow cytometry. These parameters were compared to the lymphoma prognostic criteria: disease stage, levels of lactate dehydrogenase, sed rate test, B-symptoms, Bcl-2, Ki-67 etc. Analysis of the results shows, that bone marrow lesions in primary tumors are characterized by a statistically significant increase in Bcl2-expressing cells and percentage of cells in G0-1 stage of the cell cycle, as well as decrease in percentage of cells in G2М and S stages and percentage of cells of the proliferative pool S+G2M, (G2M+S) / G0-1 compared to non-affected hematopoietic cells. Primary and recurrent lymphomas with bone marrow lesions are characterized by significant variability in cell cycle parameters describing proliferative activity of mononuclear cells combined with inefficiency of hematopoiesis. Marker cytokinetic parameters can be used as prognostic criteria for overall and relapse-free survival of patients with lymphomas.

About the Authors

K. A. Novoselova
Rostov Research Institute of Oncology
Russian Federation

Kristina A. Novoselova - MD, PhD Med, Oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



L. Yu. Vladimirova
Rostov Research Institute of Oncology
Russian Federation

Luibov Yu. Vladimirova - MD, DSc Med, oncologist, Professor, Head of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



I. B. Lysenko
Rostov Research Institute of Oncology
Russian Federation

Irina B. Lysenko - MD, DSc Med, Hematologist, Professor, Honored Medic of the Russian Federation, Head of the Oncohematology Department.

Rostov-on-Don



N. A. Abramova
Rostov Research Institute of Oncology
Russian Federation

Nataliya A. Abramova - MD, PhD Med, Oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



A. E. Storozhakova
Rostov Research Institute of Oncology
Russian Federation

Anna E. Storozhakova - MD, PhD Med, Oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



I. L. Popova
Rostov Research Institute of Oncology
Russian Federation

Irina L. Popova - MD, PhD, Oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



N. M. Tikhanovskaya
Rostov Research Institute of Oncology
Russian Federation

Nataliya M. Tikhanovskaya - MD, Oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



L. A. Ryadinskaya
Rostov Research Institute of Oncology
Russian Federation

Luidmila A. Ryadinskaya - MD, PhD Med, Oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



A. A. Lyanova
Rostov Research Institute of Oncology
Russian Federation

Aza A. Lyanova - MD, oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don



T. A. Snezhko
Rostov Research Institute of Oncology
Russian Federation

Tatyana A. Snezhko - MD, PhD Med, Oncologist of the Tumor Drug Therapy Department No. 1.

Rostov-on-Don


G. V. Salamov
Samara State Medical University (SamSMU)
Russian Federation

Georgy V. Salamov - fifth year student



References

1. Arkhipova O. E., Chernogubova E. A., Likhtanskaya N. V., Tarasov V. A., Kit O. I., Matishov D. G. Analiz vstrechaemosti onkologicheskikh zabolevanii v rostovskoi oblasti. Prostranstvenno-vremennaya statistika. Fundamental’nye issledovaniya. 2013. No. 7-3. P. 504–510 (In Russ.).

2. Kaprin A. D. Zlokachestvennye novoobrazovaniya v Rossii v 2012 godu (zabolevaemost’ i smertnost’). Eds. A. D. Kaprin, V. V. Starinskii, G. V. Petrova. Moscow: FGBU “MNIOI im. P. A. Gertsena” Minzdrava Rossii, 2014. 249 p. (In Russ.).

3. Kaprin A. D. Zlokachestvennye novoobrazovaniya v Rossii v 2012 godu (zabolevaemost’ i smertnost’). Eds. A. D. Kaprin, V. V. Starinskii, G. V. Petrova. Moscow: FGBU “MNIOI im. P. A. Gertsena” Minzdrava Rossii, 2014. 249 p. (In Russ.).

4. Kaprin A. D. Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’). Eds. A. D. Kaprin, V. V. Starinskii, G. V. Petrova. Moscow: FGBU “MNIOI im. P. A. Gertsena” filial FGBU “NMIRTs” Minzdrava Rossii, 2017. 250 p. (In Russ.).

5. Kit O. I., Shatova Yu. S., Novikova I. A., Vladimirova L. Yu., Ul’yanova E. P., Komova E. A., Kechedzhieva E. E. Ekspressiya P53 i BCL2 pri razlichnykh podtipakh raka molochnoi zhelezy. Fundamental’nye issledovaniya. 2014. No. 10-1. P. 85–88. (In Russ.).

6. Brunelle J. K., Ryan J., Yecies D., Opferman J. T., Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J. Cell Biology. 2009. Vol. 187. Р. 429–442.

7. Odenike O., Onida F., Padron E. Myelodysplastic syndromes and myelodysplastic / myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation. Am. Soc. Clin. Oncol. Educ. Book. 2015. P. e398–412.

8. Greenberg P. L., Stone R. M., Al-Kali A., Bejar R., Bennett J. M., Bloomfield C. D. et al. NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. Version 1. 2016.

9. Della Porta M. G., Tuechler H., Malcovati L., Schanz J., Sanz G., Garcia-Manero G. et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015. Vol. 29 (7). P. 1502–1513.

10. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D.W., Tubiana M. Report of the Committee on Hodgkin’s Disease Staging Classification. 1971. Cancer Res. Vol. 31 (11). P. 1860–1861.

11. Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J. Clin. Oncol. 1989. Vol. 7 (11). P. 1630–1636.

12. Lang T. A., Sesik M. Kak opisyvat’ statistiku v meditsine. Rukovodstvo dlya avtorov, redaktorov i retsenzentov: perevod s angl. Ed. V. P. Leonov. Moscow: Prakticheskaya meditsina, 2011. 480 p. (In Russ.).

13. Royston P., Parmar M. K., Altman D. G. Visualizing of survival in time-to-event studies: acompliment to Kaplan-Meier Plots. J. Natl. Cancer Inst. 2008. Vol. 100. Р. 92–97.


Review

For citations:


Novoselova K.A., Vladimirova L.Yu., Lysenko I.B., Abramova N.A., Storozhakova A.E., Popova I.L., Tikhanovskaya N.M., Ryadinskaya L.A., Lyanova A.A., Snezhko T.A., Salamov G.V. MORPHOFUNCTIONAL CHARACTERISTICS OF HEMATOPOIETIC TISSUE IN LYMPHOMA PATIENTS. Malignant tumours. 2018;8(2):5-11. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-2-5-11

Views: 1074


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)